Julius Clinical, The Netherlands   Report issue

For profit Phase 2
Founded: Zeist Netherlands (2008)

Organization Overview

First Clinical Trial
2019
NCT04165239
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Julius Clinical, The Netherlands

Active Ingredients

Drugs in Phase 2 Trials (2)

kh176 (3 trials)

trimetazidine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

MELAS Syndrome (Phase 2)

Mitochondrial Diseases (Phase 2)

Mitochondrial Encephalomyopathies (Phase 2)

Mitochondrial Myopathies (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2